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R E V I E W
Incomplete Systemic Lupus Erythematosus: What Remains 
After Application of American College of Rheumatology and 
Systemic Lupus International Collaborating Clinics Criteria?
Wietske M. Lambers, Johanna Westra, Marcel F. Jonkman, Hendrika Bootsma, and Karina de Leeuw
Incomplete systemic lupus (iSLE) is an acknowledged condition of patients with clinical signs of lupus who do not 
fulfill classification criteria for SLE. Some patients with iSLE have persistent mild disease, but others have serious 
organ involvement, and up to 55% progress to established SLE. Research on this subject could reveal predictive 
or diagnostic biomarkers for SLE. Ideally, it would become possible to discern those patients with critical organ 
involvement or a high risk for progression to SLE. This high- risk group might benefit from early treatment, which 
would preferably be confirmed in randomized controlled trials. This process would, however, require agreement 
on a definition of iSLE. The Systemic Lupus International Collaborating Clinics (SLICC) classification criteria was 
composed in order to diagnose SLE earlier. The present review outlines the clinical characteristics of iSLE after 
introduction of SLICC criteria and furthermore proposes a definition of iSLE with the aim of discriminating the high- 
risk group from those with a lower risk.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune dis-
ease that is characterized by formation of antinuclear autoantibod-
ies (ANAs) and is known to have a wide range of clinical features 
(1). The judgment of experienced physicians is generally accepted 
as the gold standard for the diagnosis of SLE; however, especially 
for research aims, accurate disease classification is important to 
create comparable, consistent study groups. For that purpose, 
the American College of Rheumatology (ACR)  criteria for SLE were 
proposed (2,3). A patient is classified as having SLE when 4 of 11 
cumulative clinical and immunologic ACR criteria are met (Table 1) 
(3). In order to increase sensitivity, the Systemic Lupus Interna-
tional Collaborating Clinics (SLICC) more recently composed new 
 criteria that were validated in 2012 (4) (Table 1). The most important 
differences between the ACR 1997 criteria and the SLICC 2012 
criteria include the merging of  criteria for subacute or acute cuta-
neous lupus and photosensitivity and addition of alternative forms 
of chronic cutaneous lupus; the addition of nonscarring alopecia as 
a clinical criterion; the redefinition of arthritis; the redefinition of the 
hematologic criteria; the separation and extension of immunologic 
criteria; the allowance of  biopsy- confirmed lupus nephritis in the 
presence of ANAs or anti– double- stranded DNA (anti- dsDNA) to 
be sufficient for classification of SLE; and the requirement of at least 
1 immunologic and 1 clinical criterion for SLE classification. Cur-
rently, new classification criteria for SLE are under review by a ACR/
European League Against Rheumatism (EULAR) collaboration (5).
Some patients with lupus symptoms still do not fulfill any of the 
current classification criteria for SLE. For example, some patients 
could have cutaneous lupus and detectable  autoantibodies but lack 
other features. Some patients have gradual disease onset and over 
time develop serious organ involvement, while others continue to 
have milder manifestations of the disease. Several terms have been 
used to qualify this heterogeneous group. The term “undifferentiated 
connective tissue disease” (UCTD) is used if autoimmunity features 
do not resemble 1 specific autoimmune disease. However, when 
patients have typical features of SLE without fulfilling the classifica-
tion criteria, the terms “latent lupus,” “early lupus,” “potential lupus,” 
“incomplete lupus,” and “incomplete SLE” have all been used (6). 
The terms “latent lupus” and “early lupus” suggest that there will be 
progression to SLE, while this is not necessarily the case. “Potential 
lupus” could be an accurate term in reference to some patients, 
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but for patients with a clear form of lupus (for example, cutaneous 
lupus), this label would not be appropriate, as they would already 
have lupus of the skin. We decided to use the term “incomplete 
SLE” (iSLE), as this can include both stable mild disease as well 
as more severe disease that is still not classifiable as SLE.
Investigating iSLE is of significant relevance, as it could reveal 
immunologic changes that occur when the disease progresses to 
SLE. Furthermore, longitudinal follow- up of these patients poten-
tially reveals predictive biomarkers that enable stratification of the 
risk for progression to established SLE. This investigation of iSLE 
would improve patient care by allowing high- risk patients to be fol-
lowed up more intensively and to possibly start treatment earlier; 
low-risk patients could be exempted from intensive follow-up and 
be reassured about disease progression. Additionally, patients 
with iSLE might benefit from inclusion in clinical trials. However, 
because patients with iSLE are probably an even more hetero-
geneous group than those with SLE, a consensus definition is of 
great importance for future research.
In the present review, the characteristics of iSLE before and 
after introduction of SLICC criteria are outlined. Moreover, clinical 
and serologic risk factors are described in order to ultimately better 
define this patient group, especially those patients at high risk of 
progression to SLE or severe organ involvement.
Characteristics of iSLE and risk factors for 
 progression to SLE
Throughout the past decades, a number of studies investi-
gating iSLE have been published. Most publications on iSLE are 
based on patients with clinical features of SLE who do not fulfill 
ACR criteria (3), and only some studies use the SLICC criteria. 
Table 2 shows an overview of these studies (7–20).
The most commonly occurring features in these patients 
are mucocutaneous symptoms (up to 46%), arthritis (up to 53%), 
and hematologic disorders (up to 52%). A significant number of 
patients with iSLE, however, have serious organ involvement. 
Up to 36% of patients with iSLE have serositis, up to 27% have 
renal involvement, and up to 6% have neurologic symptoms. 
Moreover, 53% of hospitalized iSLE patients have been found to 
have increased disease damage scores, and in 1 cohort, lupus- 
associated mortality in patients with iSLE was equal to that in 
those with SLE (15). Progression to SLE occurs in 5–57% of 
patients with iSLE within 1–10 years.
Seven studies have reported the progression rate to SLE, 
each of which are discussed herein. In the first study, by Greer 
and Panush (7), 38 patients with iSLE who were defined as meet-
ing ≥2 but <4 of the ACR criteria (2) were retrospectively com-
pared to 42 patients with SLE. At inclusion, the median disease 
duration of the iSLE group was 38 months, and the mean time 
of consecutive follow- up was 19 months. Compared to patients 
with iSLE, patients with SLE presented more frequently with malar 
rash, hematologic features, and organ involvement, whereas dis-
coid rash occurred more often in patients with iSLE. Only 5% of 
patients (n = 2) developed definite SLE (1 patient at 9 months and 
1 patient at 26 months after the first presentation); however, the 
characterisics of these patients were not published by the authors. 
At the end of follow- up of the remaining patients with iSLE, 11% 
were not classified as having a connective tissue disease, 26% 
had discoid lupus erythematosus, 5% subacute cutaneous lupus 
erythematosus, and 53% continued to have iSLE.
The second study was a prospective study conducted in 
Puerto Rico (9), in which 87 patients with iSLE were followed up 
for a mean of 2.2 years. These iSLE patients were defined as hav-
ing met ≥1 but <4 criteria according to the ACR criteria for SLE (2) 
Table 1. Overview of ACR 1997 criteria and SLICC 2012 classification criteria for SLE*
Clinical criteria Immunologic criteria














Acute or subacute cutaneous lupus
Chronic cutaneous lupus













* ACR = American College of Rheumatology; SLICC = Systemic Lupus International Collaborating Clinics; SLE 
= systemic lupus erythematosus; anti- dsDNA = anti–double- stranded DNA; ANA = antinuclear antibodies. 
† Patients were classified as having SLE when 4 of the 11 criteria were met. 
‡ Patients were classified as having SLE if 4 criteria with at least 1 clinical and 1 immunologic or biopsy- 
proven lupus nephritis and ANA or  anti- dsDNA were met. 
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and had no classification or specific symptoms of other rheumatic 
diseases. Evolution of iSLE to SLE occurred in 9% of these patients, 
with a mean interval of 4.4 years between onset of symptoms and 
diagnosis. These patients in whom iSLE progressed to SLE were 
younger than those who remained in the iSLE group (ages 24.5 
years versus 34 years), but this difference did not reach statisti-
cal significance (P = 0.06). In terms of clinical manifestations, the 
patients who developed SLE more frequently had photosensitivity, 
positive anti- dsDNA, and decreased C3 levels at baseline. Impor-
tantly, organ involvement was uncommon in both groups.
The third study was a multicenter study that prospectively 
evaluated patients with iSLE (10). For these patients, iSLE was 
defined as the presence of symptoms of 1 organ system, ANA 
positivity, and clinical suspicion of possibly developing SLE in the 
future. Although 122 patients were identified using this definition of 
iSLE, 22 already fulfilled the 1982 ACR criteria of SLE at first evalu-
ation. Of the remaining 100 patients, 3 developed SLE during the 
next 2 years. Clinical symptoms consisted mainly of fatigue, arthri-
tis, nonhemolytic anemia, and leucopenia, while organ involve-
ment was uncommon. These findings suggest that patients with 
iSLE whose illness does not progress to SLE during a short term 
represent a milder disease entity. Unfortunately, no comparison 
of baseline characteristics was made between the patients who 
developed SLE and the remaining iSLE group.
The fourth study, by Ståhl Hallengren et  al (11), included 
long- term prospective follow- up of 28 patients with iSLE, which 
was defined as ANA positivity and symptoms in ≥1 organ. After 
a median duration of 5.3 years, iSLE in 16 patients (57%) had 
progressed to SLE according to ACR criteria (2). The iSLE patients 
whose illness progressed to SLE were all ANA positive (as per 
protocol for the study), and all but 1 patient had at least 1 clinical 
symptom at baseline. The progressive patient who did not dis-
play clinical sympoms at baseline had a first- degree family mem-
ber with SLE. All 6 of the patients who had malar rash and all 6 
patients who had anticardiolipin antibodies developed established 
SLE.
In the fifth study, Laustrup et  al (12) investigated a cohort 
of 26 patients with iSLE (clinical diagnosis of SLE, not meeting 
ACR criteria) (2). All patients had detectable ANA, and the most 
prevalent clinical symptoms were photosensitivity, malar rash, and 
hematologic disorders. In 7 of these patients (27%), iSLE trans-
formed into SLE during 8 years of follow- up. No predictive factors 
could be identified.
In the penultimate study, Al Daabil et al prospectively enrolled 
264 patients who fulfilled 1–3 of the ACR classification criteria 
for SLE (14). Throughout an average follow- up time of 6.3 years, 
iSLE in 21% of patients evolved to SLE. At baseline, arthritis and 
presence of anti- dsDNA and anti- Ro/SSA were more frequent 
in the group that had eventually progressed to SLE. However, 
after multivariable logistic regression analysis, only oral ulcers, 
anti- dsDNA, and symptoms of renal involvement were found to 
be independent risk factors for the development of SLE. During 
follow- up of the group that did not develop SLE, 61% remained 
classified as having iSLE, while 18% had another diagnosis (fibro-
myalgia, autoimmune thyroid disease, mixed connective tissue 
disease, rheumatoid arthritis, or cutaneous lupus). Importantly, the 
ANA positivity rate was lower (79%) in this group compared to the 
remaining SLE group (98%).
Finally, a recent prospective observational study by Yusof et al 
(19) included 118 subjects with ANA positivity (titer ≥1:80) who 
fulfilled ≥1 clinical SLICC criteria and had symptom duration of 
<12 months. Clinical symptoms included mucocutenaous, mus-
culoskeletal, and hematologic features. During the 12 months of 
follow- up, 19 patients (16%) progressed to a classified connective 
tissue disease, of which 14 (12%) developed SLE according to 
SLICC criteria and 5 (4%) developed Sjögren’s syndrome. Two 
patients developed critical organ involment, 1 with serositis and 1 
with nephritis. All iSLE patients whose illness progressed to SLE 
had fulfilled at least 1 clinical SLICC criterion at baseline (not further 
specified by the authors), indicating that this was an important risk 
factor of disease progression. Furthermore, after logistic regres-
sion analysis, a positive family history of autoimmune rheumatic 
diseases was associated with a high risk of disease progression. 
Notably, the authors showed that interferon activity was strongly 
associated with progression to established SLE.
The above studies are extremely valuable in the underscor-
ing of the variable nature of iSLE. Importantly, most of the afore-
mentioned studies are retrospective in nature, which may result 
in underestimation of the progression rate. Logic would suggest 
that patients with a prolonged disease course are more likely to 
be included than those who quickly progressed to SLE. This is fur-
ther supported by the fact that the 2 prospective studies (11,19) 
demonstrated the highest percentage of iSLE patients whose 
illness progressed to SLE, i.e., 12% of patients after 1 year and 
57% after a median of 5.3 years. In summary, clinical symptoms 
and disease severity are highly variable among patients with 
iSLE, ranging from persistent mild disease to rapid progression 
to SLE and/or to critical organ involvement. In regard to clinical 
features, acute cutaneous lupus erythematosus, photosensitiv-
ity, serositis, ulcers, and renal involvement seem to occur more 
often in patients with iSLE whose illness progresses to SLE. These 
patients in whom iSLE progressed to SLE were younger. Further-
more, the presence of anti- dsDNA, anticardiolipin antibodies, 
and hypocomplementemia are all associated with progression to 
SLE. None of these findings, however, can accurately predict the 
 establishment of SLE.
Consequences for iSLE classification after 
 introduction of SLICC criteria
After the introduction of the SLICC criteria, various research-
ers have focused on the consequences for classification of clinically 
diagnosed lupus patients. A recent systematic review and meta- 
analysis (21) showed that for adult patients with SLE, SLICC cri-
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teria increased sensitivity compared to ACR criteria (3) (94.6% 
versus 89.6%), while specificity decreased only slightly (95.5% 
versus 98.1%). Unfortunately, most studies on iSLE have noted 
the number of ACR criteria (3) but have not published individual 
patient characteristics. Therefore, for the purpose of the present 
review, retrospective evaluation of the consequences of applying 
SLICC criteria in these patient cohorts could not be performed.
Four additional studies have applied both ACR and SLICC 
 criteria for the evalution of iSLE. In an observational study, Chen 
et al (15) included 77 hospitalized iSLE patients (iSLE being defined 
as fulfilling <4 ACR criteria [3]) in order to analyze the organ damage 
features of this group. The mean disease duration was 43 months, 
and the mean Systemic Lupus Erythematosus Disease Activity 
Index score was 6.6. When the authors applied SLICC criteria in 
this cohort, 43 patients (56%) who did not meet ACR criteria (3) 
were classified as having SLE. More than half of the patients (53%) 
had increased SLICC/ACR Damage Index scores, mostly because 
of pulmonary arterial hypertension, and renal and neurologic dam-
age. Seventeen of the 41 patients (41%) with increased damage 
scores did not meet any of the criteria sets.
In the study by Olsen et al (17) (Table 2), none of the identified 
70 patients with iSLE (which was defined as fulfilling 1–3 of the 
ACR criteria for SLE [3]) fulfilled the SLICC criteria for SLE classifi-
cation. The authors concluded that classification using the SLICC 
criteria would not change the prevalence of the incomplete lupus 
designation.
Aberle et  al (18) reviewed the medical records of 3,397 
patients with a clinical diagnosis of SLE and applied both ACR 
criteria (3) and SLICC criteria (4) in all patients. They identified 
440 subjects who only met 3 ACR criteria (3). One- third of these 
patients met SLICC criteria (4), resulting in 291 patients (9% of all 
patients with a clinical SLE diagnosis) who could not be classified 
by any of the criteria sets. A large proportion of these nonclas-
sifiable patients had organ involvement (6% serositis, 5% renal 
involvement, and 1% neurologic features) (Table 2). The majority 
of these patients were being treated with hydroxychloroquine and/
or steroids, and 10% required other immunosuppressive drugs.
Bortoluzzi et al (20) retrospectively selected 329 white patients 
with UCTD (defined as having signs and symptoms  suggestive of a 
connective tissue disease), ANA positivity, and a disease duration 
of at least 1 year who did not fulfill ACR criteria (3). In retrospect, 
44 patients (13%) already fulfilled the SLICC criteria (4) at base-
line. The most commonly occurring clinical features in this group 
were acute cutaneous lupus erythematosus (55%), leukopenia 
(39%), and synovitis (30%). Regarding critical organ involvement, 
7 patients (16%) had neurologic involvement, and 2 (5%) had 
serositis, while none had renal involvement. Of the remaining 285 
patients with UCTD, information regarding 206 could be retrieved 
from 5 to 10 years follow- up. During this period, 14 patients with 
UCTD (5%) progressed to SLE according to ACR criteria (3), and 
23 patients (8%) according to SLICC criteria (4). Unfortunately, the 
authors did not show the disease characteristics of these groups.
In summary, more patients were classified as fulfilling 
SLICC criteria than ACR criteria for SLE (3), but still ~5% of the 
patients with a clinical diagnosis remained unclassified, as can be 
expected based on sensitivity. More importantly, a considerable 
share of these patients had serious organ involvement or required 
treatment with immunosuppressive drugs and thus might benefit 
from inclusion in clinical trials.
Requirement of consensus definition for iSLE
Currently, researchers use various definitions for iSLE, which 
hinders comparability between different studies. Ideally, a classifi-
cation system would include patients who are at the highest risk of 
developing SLE or serious organ damage and exclude those who 
have prolonged mild symptoms or develop other autoimmune 
diseases. Prospective documentation of a consistent group of 
patients with iSLE is required in order to better define the high- risk 
group and to determine predictive biomarkers. We therefore ask 
for the development of a consensus on the definition of iSLE in 
order to, ideally, combine forces and start prospective documen-
tation of patients with iSLE.
Definition of iSLE involves a very heterogeneous group of 
patients and should include patients at the highest risk of develop-
ing SLE. Mucocutaneous symptoms, serositis, renal symptoms, 
anticardiolipin antibodies, low complement, and anti- dsDNA are all 
associated with progression to SLE. Table 3 shows our proposed 
Table  3. Proposed definition of incomplete systemic lupus 
erythematosus (iSLE)*
Required 
ANA at a titer ≥1:80 
And ≥1 of the following criteria†
Acute or subacute cutaneous lupus
Chronic cutaneous lupus






Or 2 of the following criteria
Hematologic manifestations‡
Immunologic features§
Positive family history of autoimmune rheumatic disease¶
And not meeting ACR 1997 criteria and/or SLICC 2012 criteria for 
SLE
* ANA = antinuclear antibody; ACR = American College of Rheu- 
matology; SLICC = Systemic Lupus International Collaborating Clinics; 
SLE = systemic lupus erythematosus. 
† As specified in SLICC classification criteria. 
‡ As specified in SLICC classification criteria. Hematologic mani-
festation included hemolytic anemia or leukopenia or lymphopenia 
(1,000/mm3 at least once) or thrombocytopenia (100,000/mm3 at 
least once). 
§ As specified in SLICC classification criteria. Immunologic features 
included anti–double- stranded DNA or anti- Sm or antiphospholipid 
antibodies or low complement or direct Coombs’ test. 
¶ Included first- or second- degree relative with autoimmune rheu-
matic disease. 
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definition of iSLE, which aims at including patients with a high risk 
of developing SLE or serious organ involvement. ANA positivity at 
a titer ≥1:80 should be present in order to be classified as iSLE, as 
this is a key feature of SLE. A recent systematic review and meta-
regression (22) on the diagnostic value of ANAs reported 97.8% 
sensitivity and 74.7% specificity for ANA at a titer ≥1:80. Also, in 
an observational study (23) on 616 patients who were referred due 
to possible SLE, 99.5% of patients with early SLE were ANA pos-
itive. The ACR/EULAR international collaboration on development 
of new classification criteria for SLE has also reached consensus 
on using positive ANA at a titer ≥1:80 as entry criterion 5.
Furthermore, a definition of iSLE should include at least 1 
clinical symptom. The study by Ståhl Hallengren et  al included 
patients fullfilling at least 1 clinical criterion, and this group had 
the highest disease progression rate compared to other longi-
tudinal studies on iSLE (11). Moreover, all patients whose illness 
progressed to iSLE who were included in the study by Yusof et al 
(19) had fulfilled a clinical criterion. We propose the usage of the 
clinical criteria as recorded in the SLICC criteria (see Table 1), as 
these criteria have been demonstrated to be more sensitive than 
ACR criteria (21).
In the absense of other clinical symptoms, hematologic 
features have been shown not to be very specific for SLE (23). 
Therefore, hematologic features should be accompanied by other 
immunologic features in order to classify iSLE. Having a first- or 
second-degree relative with an autoimmune disease has also 
been identified as a risk factor for developing SLE and should 
therefore be taken into account in the definition of iSLE. Although 
there is not much literature on this subject, we weighted this factor 
similarly to an immunologic or hematologic feature. Based on our 
review, we expect to distinguish a patient group at high risk of 
progressive disease by using this definition of iSLE.
In summary, there is still a need for better recognition of 
patients with iSLE, especially those with a high- risk profile for 
progression to SLE and/or development of organ damage. In the 
present review, an overview of the current literature was presented 
in order to clarify the characteristics of high- risk patients. Prospec-
tive documentation of a consistent group of patients with iSLE is 
necessary in order to define the high- risk group and to determine 
predictive biomarkers. Therefore, it is necessary to reach a widely 
accepted consensus on a definition for lupus patients who do not 
fulfill the classification criteria for SLE.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it critically 
for important intellectual content, and all authors approved the final version 
to be submitted for publication.
REFERENCES
 1. Bertsias GK, Pamfil C, Fanouriakis A, Boumpas DT. Diagnostic 
 criteria for systemic lupus erythematosus: has the time come? Nat 
Rev Rheumatol 2013;9:687–94.
 2. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, 
et al. The 1982 revised criteria for the classification of systemic lupus 
erythematosus. Arthritis Rheum 1982;25:1271–7.
 3. Hochberg MC, for the Diagnostic and Therapeutic Criteria Com-
mittee of the American College of Rheumatology. Updating the 
American College Of Rheumatology revised criteria for the classi-
fication of systemic lupus erythematosus [letter]. Arthritis Rheum 
1997;40:1725.
 4. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. 
Derivation and validation of the Systemic Lupus International Collab-
orating Clinics classification criteria for systemic lupus erythemato-
sus. Arthritis Rheum 2012;64:2677–86.
 5. Tedeschi SK, Johnson SR, Boumpas D, Daikh D, Dörner T, Jayne 
D, et al. Developing and refining new candidate criteria for system-
ic lupus erythematosus classification: an international collaboration. 
Arthritis Care Res (Hoboken) 2018;70:571–81.
 6. Costenbader KH, Schur PH. We need better classification and ter-
minology for “people at high risk of or in the process of developing 
lupus”. Arthritis Care Res (Hoboken) 2015;67:593–6.
 7. Greer JM, Panush RS. Incomplete lupus erythematosus. Arch Intern 
Med 1989;149:2473–6.
 8. Calvo-Alén J, Bastian HM, Straaton KV, Burgard SL, Mikhail IS, 
Alarcón GS. Identification of patient subsets among those presump-
tively diagnosed with, referred, and/or followed up for systemic 
lupus erythematosus at a large tertiary care center. Arthritis Rheum 
1995;38:1475–84.
 9. Vilá LM, Mayor AM, Valentin AH, Garcia-Soberal M, Vila S. Clinical 
outcome and predictors of disease evolution in patients with incom-
plete lupus erythematosus. Lupus 2000;9:110–5.
 10. Swaak AJ, van de Brink H, Smeenk RJ, Manger K, Kalden RJ, Tosi 
S, et al. Incomplete lupus erythematosus: results of a multicentre 
study under the supervision of the EULAR Standing Committee on 
International Clinical Studies Including Therapeutic Trials (ESCISIT). 
Rheumatology (Oxford) 2001;40:89–94.
 11. Ståhl-Hallengren C, Nived O, Sturfelt G. Outcome of incomplete 
systemic lupus erythematosus after 10 years. Lupus 2004;13: 
85–8.
 12. Laustrup H, Voss A, Green A, Junker P. SLE disease patterns in a 
Danish population- based lupus cohort: an 8- year prospective study. 
Lupus 2010;19:239–46.
 13. Olsen NJ, Li QZ, Quan J, Wang L, Mutwally A, Karp DR. Autoanti-
body profiling to follow evolution of lupus syndromes. Arthritis Res 
Ther 2012;14:R174.
 14. Al Daabil M, Massarotti EM, Fine A, Tsao H, Ho P, Schur PH, 
et al. Development of SLE among “potential SLE” patients seen 
in consultation: long- term follow- up. Int J Clin Pract 2014;68: 
1508–13.
 15. Chen Z, Li MT, Xu D, Leng XM, Wang Q, Tian XP, et al. Organ dam-
age in patients with incomplete lupus syndromes: from a chinese 
academic center. Clin Rheumatol 2015;34:1383–9.
 16. Rúa-Figueroa I, Richi P, López-Longo FJ, Galindo M, Calvo-Alén J, 
Olivé-Marqués A, et al. Comprehensive description of clinical char-
acteristics of a large systemic lupus erythematosus cohort from the 
Spanish Rheumatology Society Lupus Registry (RELESSER) with 
emphasis on complete versus incomplete lupus differences. Med-
icine (Baltimore) 2015;94:e267.
 17. Olsen NJ, McAloose C, Carter J, Han BK, Raman I, Li QZ, et al. 
Clinical and immunologic profiles in incomplete lupus erythematosus 
and improvement with hydroxychloroquine treatment. Autoimmune 
Dis 2016;2016:8791629.
 18. Aberle T, Bourn RL, Munroe ME, Chen H, Roberts VC, Guthridge 
JM, et al. Clinical and serologic features in patients with incomplete 
lupus classification versus systemic lupus erythematosus patients 
and controls. Arthritis Care Res (Hoboken) 2017;69:1780–8.
LAMBERS ET AL 614       |
 19. Md Yusof MY, Psarras A, El-Sherbiny YM, Hensor EM, Dutton K, 
Ul-Hassan S, et al. Prediction of autoimmune connective tissue dis-
ease in an at- risk cohort: prognostic value of a novel two- score sys-
tem for interferon status. Ann Rheum Dis 2018;77:1432–9.
 20. Bortoluzzi A, Furini F, Campanaro F, Govoni M. Application of SLICC 
classification criteria in undifferentiated connective tissue disease and 
evolution in systemic lupus erythematosus: analysis of a large mono-
centric cohort with a long- term follow- up. Lupus 2017;26:616–22.
 21. Hartman EA, van Royen-Kerkhof A, Jacobs JW, Welsing PM, 
Fritsch-Stork RD. Performance of the 2012 Systemic Lupus Inter-
national Collaborating Clinics classification criteria versus the 1997 
American College of Rheumatology classification criteria in adult and 
juvenile systemic lupus erythematosus. A systematic review and 
meta- analysis. Autoimmun Rev 2018;17:316–22.
 22. Leuchten N, Hoyer A, Brinks R, Schoels M, Schneider M,  Smolen 
J, et al. Performance of antinuclear antibodies for classifying sys-
temic lupus erythematosus: a systematic literature review and 
meta- regression of diagnostic data. Arthritis Care Res (Hoboken) 
2018;70:428–38.
 23. Mosca M, Costenbader KH, Johnson SR, Lorenzoni V, Sebastiani 
GD, Hoyer BF, et al. How do patients with newly diagnosed systemic 
lupus erythematosus present? A multicenter cohort of early systemic 
lupus erythematosus to inform the development of new classification 
criteria. Arthritis Rheumatol 2019;71:91–8.
